Product Code: DI 14135
Companion diagnostics are in-vitro diagnostics that provide information about
therapeutic responses of patients for a specific treatment. Companion
diagnostics market is still nascent, and it is projected to reach $3.5 billion
by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20%
during 2014 to 2020. The global companion diagnostic market is segmented based
on indication, technology and geography (North America, Europe, Asia Pacific
and LAMEA). Geographically, LAMEA is the fastest growing region. The key
drivers for this market are the increase in the discovery of biomarkers and
co-development of drug and corresponding diagnostic. However, cost associated
with developing drugs could impede the growth of this market. Opportunities
for this market lie in developing companion diagnostics for various central
nervous system conditions and hereditary conditions.
Companion Diagnostics Indication Market Analysis
Companion diagnostics is segmented on the basis of its use for indications
such as oncology, cardiovascular conditions, central nervous system
indications, inflammation and virology. Oncology is the highest revenue
generating segment, as majority of the companion diagnostics have been
developed for detection of various cancer biomarkers. The key driver for this
market is an increase in research and development of targeted drugs, which
require a corresponding companion diagnostic.
Companion Diagnostics Technology Market Analysis
Companion diagnostics technology market is segmented into Immunohistochemistry
and Molecular diagnostics. Molecular diagnostics would be the fastest growing
and highest revenue generator, mainly due to the use of techniques such as
real time PCR, In Situ Hybridization and next generation sequencing. Other
factors contributing to the growth is technological advancements in molecular
diagnostics, which has resulted in increased accuracy and precision and also
reduced cost of testing using these methods.
Companion Diagnostics Geography Market Analysis
Companion Diagnostics market has been segmented geographically into North
America, Europe, Asia Pacific and LAMEA. North America has the major market
share of 43.97% followed by Europe, which accounted for about 38% of the
overall CD market in 2013. North America and Europe together accounted for
over 82% in the global CD market in 2013 and they would continue to be the
major markets through 2020. This is mainly due to the increasing incidence of
cancer and other diseases and higher health care awareness in these regions.
Competitive Analysis
A study of some of the key players has showed that majority of the companies
in this market are focusing on collaborations with drug companies. Companion
diagnostics is a emerging market and companies are collaborating with drug
companies to develop companion diagnostics for their pipeline drugs, which are
in developing phase. Approvals for companion diagnostics are the second most
popular strategy. Companies profiled in this report include Dako (Agilent
Technologies), Qiagen, Roche, Abbott Laboratories, Inc., Ventana Medical
Systems, bioMerieux, Myriad Genetics, Inc., Resonance Health Ltd., Leica
Microsystems, and Life Technologies.
High Level Analysis
The report is focusing on the trends in technology and diagnosis of various
indications, which are driving the growth of the companion diagnostics market.
Analysis of the market based on porters five force model shows that the
bargaining power of the suppliers is high as the products produced are highly
differentiated. The threat of new entrants is low as significant research and
development is required for developing diagnostic tests. Apart from the R&D
requirements, the investment required is also high. These factors make it
difficult for new companies to enter the market. The threat of substitutes is
low in this market as companion diagnostics are developed for specific
biomarkers and the products are highly differentiated. Competition in this
market is moderate as the market is still emerging and there are a few
companies in the market. Government regulations are favoring use of companion
diagnostics for determining a particular treatment. Companies are focusing on
collaborations with pharmaceutical companies as a key strategy to gain
competitive advantage.
Reason for doing the study
Companion diagnostics are an important aspect of the personalized treatment
approach and are essential for predicting the therapeutic response to a
particular drug. With increasing awareness among the population and rising
incidences of cancer, companion diagnostics would become an essential factor
for targeted therapeutic approach. More and more companies are developing
targeted therapeutics products and companion diagnostics is an integral part
of their strategy.
KEY BENEFITS
- In-depth analysis of the companion diagnostic market by technology and
indications give a clear idea of the scope of this market
- Analysis of the market by geography would help in making region specific
plans
- Estimations for period of 2013 to 2020 have been given, taking into
consideration the current market scenario and future trends, which would give
a clearer picture of the potential of the market
- Porter's five force model and SWOT analysis would help in a deeper
understanding of the market and help in making strategic decisions
- Top factors impacting the market would help in making decisions for
business development
KEY DELIVERABLES
MARKET BY INDICATIONS
- Oncology
- Cardiovascular
- Central Nervous System
- Auto immune & Inflammation
- Virology
- Others
MARKET BY TECHNOLOGY
- Immunohistochemistry
- Molecular diagnostics
- In situ Hybridization
- FISH
- CISH
- Real time PCR
- Gene Sequencing
MARKET BY GEOGRAPHY
- North America
- Europe
- Asia Pacific
- LAMEA
Table of Contents
CHAPTER 1 - INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Research methodology
- 1.3.1. Secondary research
- 1.3.2. Primary research
- 1.3.3. Analyst tools and models
CHAPTER 2 - EXECUTIVE SUMMARY
CHAPTER 3 - MARKET OVERVIEW
- 3.1. Market Definition and Scope
- 3.2. Companion Diagnostics for Metabolic Diseases
- 3.3. Novel trends and technologies in companion diagnostics assay
development
- 3.4. Companion diagnostics as a new trend in personalized medicine
- 3.5. Biomarkers market as basis for the companion diagnostics industry
- 3.6. Key Findings
- 3.6.1. Top Factors Impacting The Companion Diagnostic Market
- 3.6.2. Top Winning Strategies
- 3.7. Porter's five forces analysis
- 3.7.1. High switching cost leads to higher bargaining power of suppliers
- 3.7.2. Highly differentiated products leads to lower bargaining power of
buyers
- 3.7.3. Specificity of diagnostics lowers the threat of substitutes
- 3.7.4. Higher capital investment leads to lesser threat of entrants
- 3.7.5. Few competitors leads to low competition among players
- 3.8. Government Regulations
- 3.8.1. FDA regulations
- 3.8.2. Europe
- 3.8.3. Japan
- 3.8.4. China
- 3.9. Value Chain Analysis
- 3.10. Case Study
- 3.11. Drivers
- 3.11.1. Increased popularity of Personalized medicine
- 3.11.2. Increasing cases of adverse drug reactions(ADRs)
- 3.11.3. Increase in the Discovery of Biomarkers as drug targets.
- 3.11.4. Rising success of co-development drugs speedily approved by the
FDA
- 3.11.5. Technological advancements
- 3.11.6. Rising incidences of diseases
- 3.12. Restraints
- 3.12.1. High Cost in research and development of drugs
- 3.12.1.1. Economic and scientific obstacles
- 3.12.2. Opportunities
- 3.12.2.1. Opportunities in treatment of neurodegenerative diseases
- 3.12.2.2. Companion diagnostics for hereditary mutations
CHAPTER 4 - GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATIONS
- 4.1. Oncology
- 4.1.1. Companion diagnostics oncology market by geography,
- 4.1.2. Breast Cancer
- 4.1.2.1. companion diagnostics breast cancer market by geography
- 4.1.3. Lung Cancer
- 4.1.3.1. companion diagnostics lung cancer market by geography
- 4.1.4. Colorectal Cancer
- 4.1.4.1. companion diagnostics Colorectal Cancer market by geography
- 4.1.5. Gastric cancer
- 4.1.5.1. companion diagnostics Gastric Cancer market by geography
- 4.1.6. Melanomas
- 4.1.6.1. companion diagnostics Melanoma market by geography
- 4.2. Inflammation and Autoimmune diseases
- 4.2.1. Companion diagnostics inflammation market by geography
- 4.3. Companion diagnostics in cardiovascular diseases
- 4.3.1. Companion diagnostics tests for warfarin
- 4.3.2. Companion diagnostics cardiovascular market by geography
- 4.4. Companion diagnostics in CNS disorders
- 4.4.1. Companion diagnostics CNS market by geography
- 4.5. Companion diagnostics tests in virology diseases
- 4.5.1. Companion diagnostics virology market by geography
- 4.6. Others
- 4.6.1. Companion diagnostics others market by geography
CHAPTER 5 - GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY
- 5.1. Companion diagnostics technology market by geography
- 5.2. Immunohistochemistry
- 5.2.1. Companion diagnostics Immmunohistochemistry market by geography
- 5.3. Molecular Diagnostics
- 5.3.1. Companion diagnostics molecular diagnostics market by types
- 5.3.2. Companion diagnostics Molecular Diagnostics market by geography
- 5.3.3. In-situ Hybridization
- 5.3.3.1. Fluorescent In-situ Hybridization(FISH)
- 5.3.3.2. CISH (Chromogenic In-Situ Hybridization)
- 5.3.3.3. Companion diagnostics In situ Hybridization market by
geography
- 5.3.4. Real Time PCR
- 5.3.4.1. Companion diagnostics RT PCR market by geography
- 5.3.5. Gene Sequencing
- 5.3.5.1. Companion diagnostics Sequencing market by geography
- 5.3.6. Others
- 5.3.6.1. Others molecular companion diagnostics market by geography
CHAPTER 6 - GLOBAL COMPANION DIAGNOSTICS BY GEOGRAPHY
- 6.1. North America
- 6.1.1. Companion diagnostics North America market by indication
- 6.2. Europe
- 6.2.1. Companion diagnostics Europe market by indication
- 6.3. Asia Pacific
- 6.3.1. Companion diagnostics Asia Pacific market by indication
- 6.4. RoW
- 6.4.1. Companion diagnostics RoW market by indication
CHAPTER 7 - COMPANY PROFILES
- 7.1. Qiagen
- 7.1.1. Company Overview:
- 7.1.2. Company Snapshot
- 7.1.3. Business Performance
- 7.1.4. Strategy move and development
- 7.1.4.1. Principal strategies Collaborations
- 7.1.4.2. Secondary Strategies Approval
- 7.1.5. SWOT Analysis of Qiagen
- 7.2. Dako (Agilent Technologies)
- 7.2.1. Company Overview
- 7.2.2. Company Snapshot
- 7.2.3. Business Performance
- 7.2.4. Strategic Moves and Development
- 7.2.4.1. Principal strategies Collaboration
- 7.2.4.2. Secondary Strategies Approval
- 7.2.5. SWOT Analysis of Dako
- 7.3. Roche
- 7.3.1. Company overview
- 7.3.2. Company Snapshot
- 7.3.3. Business Performance
- 7.3.4. Strategies move and development
- 7.3.5. SWOT analysis of Roche
- 7.4. Abbott Laboratories, Inc.
- 7.4.1. Company Overview
- 7.4.2. Company Snapshot
- 7.4.3. Business Performance
- 7.4.4. Principal Strategies Collaboration
- 7.4.5. SWOT Analysis of Abbot
- 7.5. BioMerieux
- 7.5.1. Company Overview
- 7.5.2. Company snapshot:
- 7.5.3. Business Performance
- 7.5.4. Strategies and development Approval
- 7.5.5. SWOT Analysis of BioMerieux,
- 7.6. Ventana Medical Systems
- 7.6.1. Company Profile
- 7.6.2. Company Snapshot
- 7.6.3. Business Performance
- 7.6.4. Strategies and development
- 7.6.5. SWOT Analysis of Ventana
- 7.7. Myriad Genetics, Inc.
- 7.7.1. Company Overview
- 7.7.2. Company snapshot
- 7.7.3. Business Performance
- 7.7.4. Strategies and development
- 7.7.5. SWOT Analysis of Myraid
- 7.8. Resonance Health Ltd
- 7.8.1. Company Overview
- 7.8.2. Company Snapshot
- 7.8.3. Strategies move and development
- 7.8.4. SWOT Analysis of Ferriscan
- 7.9. Leica Microsystems
- 7.9.1. Company overview
- 7.9.2. Company Snapshot
- 7.9.3. Strategies move and Development
- 7.9.4. SWOT Analysis of Leica Microsystems
- 7.10. Life Technologies
- 7.10.1. Company Overview
- 7.10.2. Company Snapshot
- 7.10.3. Business performance
- 7.10.4. Strategies move and Development
- 7.10.5. SWOT Analysis of Life Technologies
LIST OF TABLES:
- TABLE 1: GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2013-2020
($MILLION)
- TABLE 2: COMPANION DIAGNOSTICS INDICATION MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
- TABLE 3: GLOBAL COMPANION DIAGNOSTICS MARKET BY ONCOLOGY, 2013-2020,
($MILLION)
- TABLE 4: COMPANION DIAGNOSTICS ONCOLOGY MARKET BY GEOGRAPHY, 2013-2020,
($MILLION)
- TABLE 5: COMPANION DIAGNOSTICS BREAST CANCER MARKET BY GEOGRAPHY,
2013-2020 ($MILLION)
- TABLE 6: COMPANION DIAGNOSTICS LUNG CANCER MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
- TABLE 7: COMPANION DIAGNOSTICS COLORECTAL CANCER MARKET BY GEOGRAPHY,
2013-2020 ($MILLION)
- TABLE 8: COMPANION DIAGNOSTICS GASTRIC CANCER MARKET BY GEOGRAPHY,
2013-2020 ($MILLION)
- TABLE 9: COMPANION DIAGNOSTICS MELANOMA MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
- TABLE 10: COMPANION DIAGNOSTICS INFLAMMATION MARKET BY GEOGRAPHY,
2013-2020 ($MILLION)
- TABLE 11: COMPANION DIAGNOSTICS CARDIOVASCULAR MARKET BY GEOGRAPHY,
2013-2020 ($MILLION)
- TABLE 12: COMPANION DIAGNOSTICS CNS MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
- TABLE 13: COMPANION DIAGNOSTICS VIROLOGY MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
- TABLE 14: COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
- TABLE 15: COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY TECHNOLOGY 2013-2020
($MILLION)
- TABLE 16: COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
- TABLE 17: COMPANION DIAGNOSTICS IMMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY,
2013-2020 ($MILLION)
- TABLE 18: COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY TYPES
2013-2020 ($MILLION)
- TABLE 19: COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY,
2013-2020 ($MILLION)
- TABLE 20: COMPANION DIAGNOSTICS IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY,
2013-2020 ($MILLION)
- TABLE 21: COMPANION DIAGNOSTICS RT PCR MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
- TABLE 22: COMPANION DIAGNOSTICS SEQUENCING MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
- TABLE 23: OTHERS MOLECULAR COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY,
2013-2020 ($MILLION)
- TABLE 24: COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
- TABLE 25: COMPANION DIAGNOSTICS NORTH AMERICA MARKET, 2013-2020 ($MILLION)
- TABLE 26: COMPANION DIAGNOSTICS EUROPE MARKET, 2013-2020 ($MILLION)
- TABLE 27: COMPANION DIAGNOSTICS ASIA-PACIFIC MARKET, 2013-2020 ($MILLION)
- TABLE 28: COMPANION DIAGNOSTICS ROW MARKET, 2013-2020 ($MILLION)
- TABLE 29: QIAGEN SNAPSHOT
- TABLE 30: DAKO COMPANY SNAPSHOT
- TABLE 31: ROCHE COMPANY SNAPSHOT
- TABLE 32: ABBOTT COMPANY SNAPSHOT
- TABLE 33: BIOMERIEUX COMPANY SNAPSHOT
- TABLE 34: VENTANA COMPANY SNAPSHOT
- TABLE 35: MYRIAD COMPANY SNAPSHOT
- TABLE 36: RESONANCE COMPANY SNAPSHOT
- TABLE 37: LEICA COMPANY SNAPSHOT
- TABLE 38: LIFE TECHNOLOGIES COMPANY SNAPSHOT
LIST OF FIGURES:
- FIG.1: OMPANION DIAGNOSTICS AS A NEW TREND IN PERSONALIZED MEDICINE
- FIG.2: FFECTIVENESS OF COMPANION DIAGNOSTICS IN LUNG CANCER PATIENTS
- FIG.3: IST BIOMARKERS AND THE COMPANION DIAGNOSTICS FOR VARIOUS DISEASES
- FIG.4: OP FACTORS IMPACTING THE COMPANION DIAGNOSTIC MARKET
- FIG.5: OP WINNING STRATEGIES
- FIG.6: ALUE CHAIN ANALYSIS
- FIG.7: INANCIAL REVENUES BY BUSINESS UNITS (2013)
- FIG.8: INANCIAL REVENUES BY GEOGRAPHY(2013)
- FIG.9: WOT ANALYSIS OF QIAGEN
- FIG.10: INANCIAL REVENUE OF DAKO, BY SEGMENT (2012)
- FIG.11: WOT ANALYSIS OF DAKO
- FIG.12: INANCIAL REVENUE OF DAKO, BY SEGMENT
- FIG.13: INANCIAL REVENUE OF DAKO, BY GEOGRAPHY
- FIG.14: WOT ANALYSIS OF ROCHE
- FIG.15: EVENUE BY BUSINESS SEGMENTS
- FIG.16: EVENUE BY GEOGRAPHY
- FIG.17: WOT ANALYSIS OF ABBOTT
- FIG.18: INANCIAL REVENUES BY GEOGRAPHY
- FIG.19: INANCIAL REVENUES BY TECHNOLOGY
- FIG.20: WOT ANALYSIS OF BIOMERIEUX
- FIG.21: WOT ANALYSIS OF VENTANA
- FIG.22: EVENUE BY DIAGNOSTIC TYPE
- FIG.23: WOT ANALYSIS OF MYRAID
- FIG.24: WOT ANALYSIS OF FERRISCAN
- FIG.25: WOT ANALYSIS OF LEICA MICROSYSTEMS
- FIG.26: EVENUE BY END MARKETS
- FIG.27: WOT ANALYSIS OF LIFE TECHNOLOGIES
